Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage
Globe Newswire•10/08/2026•09:01 ET
0
Whiz Insights
Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance
Appointment further strengthens leadership team at a pivotal inflection point as Company positions ERNA-101 for planned IND submission in Q3 2026 and Phase 1 clinical study initiation in the Q4 2026
Get started
Create a free account to read the full story.